HCPCS Level II J1595: Injection, glatiramer acetate, 20 mg - OpenPayer

Summary & Overview

HCPCS Level II J1595: Injection, glatiramer acetate, 20 mg

HCPCS Level II code J1595 denotes a 20 mg injection of glatiramer acetate, an immunomodulatory agent used as a disease-modifying therapy in outpatient specialty care. The code is central to billing for administered doses of glatiramer acetate across physician offices, specialty infusion or injection centers, and other ambulatory settings. Nationally, J1595 matters because it standardizes billing for a commonly used injectable therapy, affecting reimbursement workflows, prior authorization processes, and specialty drug reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1595 represents clinically and operationally, plus context on payer coverage patterns and common claims handling considerations. The publication highlights benchmarks and policy-relevant points such as coding specificity for dose-based billing, implications for site-of-service reimbursement, and the role of HCPCS Level II coding in specialty medication administration.

This summary equips revenue cycle, pharmacy, and clinician stakeholders with the essential information needed to identify the code, understand its typical use cases, and locate further details on coverage and billing practices. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ1595HCPCS Level IIglatiramer acetateinjectable medicationspecialty pharmacyoutpatient caredrug administrationmedical billingrevenue cycle

Billing Code Overview

HCPCS Level II code J1595 represents Injection, glatiramer acetate, 20 mg. This code describes a single-dose injectable formulation of glatiramer acetate, an immunomodulatory medication commonly used in outpatient specialty settings for disease-modifying therapy.

Service Type: Injectable medication administration

Typical Site of Service: Outpatient clinics, specialty infusion or injection centers, and physician offices

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult diagnosed with relapsing-remitting multiple sclerosis (MS) receiving outpatient subcutaneous therapy with glatiramer acetate, 20 mg. The patient presents to an infusion or specialty pharmacy clinic for medication administration or to a neurology clinic for training on self-injection. The clinical workflow includes verification of the prescription for J1595, pre-administration screening for allergies and infection, assessment of recent relapses and baseline vital signs, patient education on injection technique and adverse effects (for example, injection-site reactions, transient chest tightness or flushing), preparation and administration of the 20 mg glatiramer acetate dose via subcutaneous injection, documentation of lot number and expiration, and post-injection observation for immediate reactions. Billing for the medication uses J1595 and may be accompanied by appropriate visit or injection administration CPT codes, device or supply charges, and modifiers to indicate special circumstances (for example, patient status or service component). Typical sites of service include outpatient infusion/administration clinics, neurology offices, specialty pharmacy clinics, and the patient’s home when administered by a qualified clinician or under a home health plan arrangement.

Coding Specifications

Modifier	Description	When to Use
`00`

Related Codes

HCPCS-J2941-SOMATROPIN-INJECTION-1-MG

HCPCS J2941: Injection, Somatropin, 1 mg

HCPCS-J7500-AZATHIOPRINE-ORAL-50MG

HCPCS J7500: Azathioprine, Oral, 50 mg

HCPCS-J2150-MANNITOL-25PCT-50ML-INJECTION

HCPCS Level II J2150: Injection, Mannitol 25% in 50 mL

HCPCS-J2360-ORPHENADRINE-INJECTION-UP-TO-60-MG

HCPCS J2360: Orphenadrine Injection, Up to 60 mg

HCPCS-J1164-DILTIAZEM-INJECTION-0-5-MG

HCPCS J1164: Diltiazem Hydrochloride Injection, 0.5 mg

HCPCS-J0801-CORTICOTROPIN-ACTHAR-GEL-INJECTION-40-UNITS

HCPCS J0801: Corticotropin (Acthar Gel) Injection, up to 40 Units

HCPCS-J1746-IBALIZUMAB-INJECTION-10MG

HCPCS J1746: Ibalizumab-uiyk Injection, 10 mg

HCPCS-J0744-CIPROFLOXACIN-IV-INFUSION-200MG

HCPCS Level II J0744: Ciprofloxacin Injection for Intravenous Infusion, 200 mg

HCPCS-J1738-MELOXICAM-INJECTION-1MG

HCPCS Level II J1738: Injection, meloxicam, 1 mg

HCPCS-J1806-ESMOLOL-INJECTION-CRITICAL-CARE-10MG

HCPCS J1806: Esmolol Hydrochloride Injection, 10 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`2084P0800X`	Neurology	Neurologists commonly prescribe and oversee disease-modifying therapy for multiple sclerosis, including `J1595`.
`363LP0800X`	Nurse Practitioner	Nurse practitioners in neurology or specialty clinics administer injections and provide patient education.
`367A00000X`	Physician Assistant	Physician assistants often perform medication administration and clinic visits for MS patients.
`1744S0200X`	Infusion Nurse	Infusion or specialty nurses administer subcutaneous injections in clinic settings and manage adverse events.
`3336C0002X`	Clinical Pharmacist	Clinical pharmacists in specialty pharmacies prepare, dispense, and counsel patients on glatiramer acetate therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary indication for treatment with glatiramer acetate; used for disease-modifying therapy in relapsing forms of MS.
`G36.0`	Acute disseminated encephalitis and encephalomyelitis following immunization	Rare differential; included for completeness when neurologic demyelinating events are being evaluated prior to initiating therapy.
`G37.9`	Demyelinating disease of central nervous system, unspecified	Used when a specific demyelinating disorder is documented but not further specified; may be used in initial coding pending neurologic workup.
`M79.1`	Myalgia	Symptom code for muscle pain which can be relevant when documenting injection-site or systemic musculoskeletal adverse effects.
`T88.1`	Other complications following immunization, not elsewhere classified	Used to document adverse reactions temporally associated with injections if applicable.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing long-term therapy with disease-modifying agents when required by payer documentation.
`Z51.89`	Encounter for other specified aftercare	Used for follow-up visits related to ongoing therapy management and monitoring after administration of a chronic injectable agent.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly used to report the professional service of administering a subcutaneous injection of glatiramer acetate when billed separately from the drug supply.
`90471`	Immunization administration (includes percutaneous, intranasal, or oral) — first or only component	Occasionally used by payers for counseling and administration-type services; less typical for prescription biologic injectables but included where administration codes are required.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic	Not routinely used for glatiramer acetate; listed for clinical workflow distinction when oncology-style infusion billing rules are present (use payer guidance).
`99001`	Handling and/or processing of a single dose injectable medication by a pharmacy or licensed practitioner (facility-specific)	Used in some facility billing scenarios for preparation/handling of specialty injectable medications.
`G0498`	Administration of a medication through a subcutaneous infusion pump or catheter; per 30-day supply (Medicare-specific)	Relevant only if the medication is delivered via an approved pump/catheter system — generally not applicable to standard self-injection but included for completeness.
`S4993`	Injectable drug administration, subcutaneous or intramuscular (payer-specific HCPCS-level)	Payer-specific codes sometimes appear alongside `J` drug codes for administration reporting; check payer policies for appropriate use.